| Arcturus Therapeutics Holdings is a global clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and other opportunities within liver and respiratory rare diseases. Co.'s coronavirus disease 2019 vaccine candidate, ARCT-021, is designed to promote immune responses to the spike protein of the Severe Acute Respiratory Syndrome-2 virus, which is the part of the virus that allows infection to occur. The LUNAR-OTC development program addresses ornithine transcarbamylase (OTC) deficiency, a genetic disease caused by mutations in the OTC gene that lead to dysfunctional or deficient OTC. The LUNAR-CF program addresses cystic fibrosis lung disease. We show 16 historical shares outstanding datapoints in our ARCT shares outstanding history coverage, used to compute ARCT market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARCT market cap history over the course of time is important for investors
interested in comparing ARCT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARCT versus a peer is one thing; comparing
ARCT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARCT can fluctuate over the course of history.
With this page we aim to empower investors researching ARCT by allowing them to research the ARCT market cap history.